These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19406000)

  • 1. Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice.
    Kodama A; To H; Kinoshita T; Ieiri I; Higuchi S
    J Pharm Pharmacol; 2009 May; 61(5):615-21. PubMed ID: 19406000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice.
    Tabuchi M; To H; Sakaguchi H; Goto N; Takeuchi A; Higuchi S; Ohdo S
    Cancer Res; 2005 Sep; 65(18):8448-54. PubMed ID: 16166324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice.
    To H; Shin M; Tabuchi M; Sakaguchi H; Takeuchi A; Matsunaga N; Higuchi S; Ohdo S
    Clin Cancer Res; 2004 Jan; 10(2):762-9. PubMed ID: 14760099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
    Granda TG; Filipski E; D'Attino RM; Vrignaud P; Anjo A; Bissery MC; Lévi F
    Cancer Res; 2001 Mar; 61(5):1996-2001. PubMed ID: 11280758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
    Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
    Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiation therapy with docetaxel/cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study.
    Huber RM; Borgmeier A; Flentje M; Willner J; Schmidt M; Manegold C; Bramlage P; Debus J
    Clin Lung Cancer; 2010 Jan; 11(1):45-50. PubMed ID: 20085867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
    Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
    Yamamoto N; Nishimura Y; Nakagawa K; Matsui K; Fukuoka M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):285-91. PubMed ID: 16416334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
    Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
    Le Chevalier T; Bérille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.